Abstract     Description     Claims     Drawing  

US5399578A   [0044] 
EP0443983A   [0044] 
US4722810A   [0052] 
US5223516A   [0052] 
US4610816A   [0052] 
US4929641A   [0052] 
ZA840670   [0052] 
GB69578A   [0052] 
US5217996A   [0052]  [0052]  [0055] 
EP00342850A   [0052] 
GB02218983A   [0052] 
WO9214706A   [0052] 
EP00343911A   [0052] 
JP06234754B   [0052] 
EP00361365A   [0052] 
WO9009374A   [0052] 
JP07157459B   [0052] 
WO9415908A   [0052] 
US5273990A   [0052] 
US5294632A   [0052] 
US5250522A   [0052] 
EP00636621A   [0052] 
WO9309101A   [0052] 
EP00590442A   [0052] 
WO9310773A   [0052] 

Pharmacol Rev   [0003] 
J Hypertens   [0003] 
J Clin Pharmacol   [0003] 
Peptides   [0003] 
Lancet   [0004] 
Hypertension   [0004] 
Chem Pharm Bull   [0066] 
Ray Structure Determination; A Practical Guide   [0079] 
Expert Opin Investig Drugs   [0094] 
High human renin hypertension in transgenic rats   [0098] 
CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme   [0100]